(S)-Enitociclib

Description: (S)-Enitociclib (VIP152) is a selective CDK9 inhibitor that induces complete regression of MYC+ lymphomas by inhibiting RNA polymerase II-mediated transcription of anti-apoptotic and pro-survival proteins. Target: CDK. Smiles: COC1=C(C2=C(F)C=NC(NC3=CC(C[S@@](C)(=N)=O)=CC=N3)=C2)C=CC(F)=C1. References: Lücking U,et al. Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer. J Med Chem. 2021 Aug 12,64(15):11651-11674.